



Correction to: Anti-inflammatory, anti-rheumatic and analgesic activities of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-*N*-propylbenzenesulphonamide (MOPBS) in rodents

Hina Rasheed¹ · Ruqayya Afridi¹ · Ashraf Ullah Khan¹ · Muhammad Zia Ullah¹ · Sidra Khalid¹ · Ayesha Atiq¹ · Humaira Kashif² · Muhammad Naeem Ahmed² · Yeong Shik Kim³ · Salman Khan^{1,3}

Published online: 10 March 2018
© Springer International Publishing AG, part of Springer Nature 2018

Correction to: Inflammopharmacology
<https://doi.org/10.1007/s10787-018-0446-4>

Unfortunately, Fig. 1 was incorrectly published in the original publication. The corrected Fig. 1 is given below.

The original article can be found online at <https://doi.org/10.1007/s10787-018-0446-4>.

✉ Yeong Shik Kim
kims@snu.ac.kr

✉ Salman Khan
skhan@qau.edu.pk

¹ Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan

² Department of Chemistry, University of Azad Jammu and Kashmir, Muzaffarabad, Azad Kashmir, Pakistan

³ College of Pharmacy, Seoul National University, Seoul 151-742, South Korea




Fig. 1 **a** Structure of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-N-propylbenzenesulphonamide (MOPBS). **b** MOPBS (1, 10, 50 and 100 mg/kg) pretreatment reduced carrageenan-induced paw oedema. The paw thickness was measured after 4 h of carrageenan injection. **c** MOPBS (1, 10, 50 and 100 mg/kg) pretreatment inhibited carrageenan-induced mechanical hyperalgesia, **d** mechanical allodynia and **e** ther-

mal hyperalgesia. The paw withdrawal effect was measured after 4 h of carrageenan injection. The data are expressed as the mean \pm SD (* $p < 0.01$, (** $p < 0.001$ and (***) $p < 0.0001$ show a significant difference from carrageenan-induced group. (###) denotes comparison of vehicle control group (normal group) and carrageenan-induced group with MOPBS-treated group